---
title: Effects of an initial anti-CD19 CAR T-cell therapy on subsequent anti-CD22
  CAR T-cell manufacturing and clinical outcomes in patients with r/r LBCL
date: '2025-01-08'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39775812/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20250109170927&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Patients with large B-cell lymphoma (LBCL) progressing after anti-CD19
  CAR T-cell (CAR19) therapy have poor outcomes. Subsequent CAR T-cell therapy shows
  promise, but the impact of residual CAR19 and early relapse remains unclear. We
  evaluated 37 CAR19-refractory LBCL patients who received anti-CD22 CAR T-cell (CAR22)
  in a phase 1b trial (NCT04088890). Residual CAR19 was unquantifiable in 17 of 33
  evaluable patients post-CAR22 infusion. Single-cell RNA sequencing revealed minimal
  ...
disable_comments: true
---
Patients with large B-cell lymphoma (LBCL) progressing after anti-CD19 CAR T-cell (CAR19) therapy have poor outcomes. Subsequent CAR T-cell therapy shows promise, but the impact of residual CAR19 and early relapse remains unclear. We evaluated 37 CAR19-refractory LBCL patients who received anti-CD22 CAR T-cell (CAR22) in a phase 1b trial (NCT04088890). Residual CAR19 was unquantifiable in 17 of 33 evaluable patients post-CAR22 infusion. Single-cell RNA sequencing revealed minimal ...